SGHT vs. INO, TLSI, GUTS, UTMD, ANGO, RCEL, CERS, TCMD, LUNG, and PROF
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include Inovio Pharmaceuticals (INO), TriSalus Life Sciences (TLSI), Fractyl Health (GUTS), Utah Medical Products (UTMD), AngioDynamics (ANGO), AVITA Medical (RCEL), Cerus (CERS), Tactile Systems Technology (TCMD), Pulmonx (LUNG), and Profound Medical (PROF). These companies are all part of the "surgical & medical instruments" industry.
Inovio Pharmaceuticals (NASDAQ:INO) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment.
26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 2.5% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 27.1% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sight Sciences has higher revenue and earnings than Inovio Pharmaceuticals. Sight Sciences is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Inovio Pharmaceuticals received 702 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 71.49% of users gave Inovio Pharmaceuticals an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
Inovio Pharmaceuticals presently has a consensus target price of $70.67, indicating a potential upside of 532.65%. Sight Sciences has a consensus target price of $4.70, indicating a potential downside of 13.76%. Given Sight Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Sight Sciences.
In the previous week, Inovio Pharmaceuticals had 16 more articles in the media than Sight Sciences. MarketBeat recorded 17 mentions for Inovio Pharmaceuticals and 1 mentions for Sight Sciences. Inovio Pharmaceuticals' average media sentiment score of 1.22 beat Sight Sciences' score of 0.42 indicating that Sight Sciences is being referred to more favorably in the news media.
Sight Sciences has a net margin of -67.18% compared to Sight Sciences' net margin of -16,238.91%. Inovio Pharmaceuticals' return on equity of -44.45% beat Sight Sciences' return on equity.
Inovio Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.73, indicating that its stock price is 173% more volatile than the S&P 500.
Summary
Sight Sciences beats Inovio Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
